<DOC>
	<DOC>NCT00561301</DOC>
	<brief_summary>- To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)</brief_summary>
	<brief_title>Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma</brief_title>
	<detailed_description>- The feasibility will be evaluated in terms of objective response rate, efficacy of stem cell collection, disease-free survival, and overall survival.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>Patients who have refractory to firstline CHOPlike regimen Patients who have first relapse after firstline CHOPlike regimen upfront autologous or allogeneic hematopoietic stem cell transplantation Age 15 years or more ECOG performance status â‰¤ 2 Adequate bone marrow function Adequate kidney,liver,cardiac Patients who have received GEM or OX</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>